Neurocrine Biosciences (MIL:1NBIX) Cyclically Adjusted Book per Share: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1NBIX Neurocrine Biosciences Inc MIL:1NBIX
74 GF Score
Price €159.45
GF Value €165.48
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Cyclically Adjusted Book per Share?

Neurocrine Biosciences MIL:1NBIX 74 Cyclically Adjusted Book per Share is €0.00 as of Jun. 2026. GuruFocus rates MIL:1NBIX with a GF Score™ of 74/100 and a GF Value™ of €165.48 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Neurocrine Biosciences's adjusted book value per share for the three months ended in Jun. 2026 was €30.768. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Neurocrine Biosciences's average Cyclically Adjusted Book Growth Rate was 22.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 24.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 27.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Neurocrine Biosciences was 31.30% per year. The lowest was -18.70% per year. And the median was -2.70% per year.

As of today (2026-07-31), Neurocrine Biosciences's current stock price is €159.45. Neurocrine Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €0.00. Neurocrine Biosciences's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Neurocrine Biosciences was 47.47. The lowest was 7.19. And the median was 16.05.


Neurocrine Biosciences  (MIL:1NBIX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Neurocrine Biosciences was 47.47. The lowest was 7.19. And the median was 16.05.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Neurocrine Biosciences Cyclically Adjusted Book per Share Related Terms


Neurocrine Biosciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Cyclically Adjusted Book per Share Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 12.83

Neurocrine Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.34 11.71 12.83 13.50 0.00

MIL:1NBIX vs VTRS, UTHR, ELAN: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted PB Ratio falls into.


MIL:1NBIX
74GF Score
Neurocrine Biosciences Inc MIL:1NBIX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Neurocrine Biosciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=30.768/333.9520*333.9520
=30.768

Current CPI (Jun. 2026) = 333.9520.

Neurocrine Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.607 241.428 4.989
201612 3.436 241.432 4.753
201703 2.640 243.801 3.616
201706 3.483 244.955 4.748
201709 3.296 246.819 4.460
201712 3.541 246.524 4.797
201803 3.289 249.554 4.401
201806 3.574 251.989 4.736
201809 4.230 252.439 5.596
201812 4.654 251.233 6.186
201903 3.968 254.202 5.213
201906 4.677 256.143 6.098
201909 5.665 256.759 7.368
201912 6.212 256.974 8.073
202003 6.829 258.115 8.835
202006 7.920 257.797 10.260
202009 7.311 260.280 9.380
202012 9.901 260.474 12.694
202103 10.716 264.877 13.511
202106 11.223 271.696 13.795
202109 12.069 274.310 14.693
202112 12.813 278.802 15.348
202203 13.226 287.504 15.363
202206 14.085 296.311 15.874
202209 16.234 296.808 18.266
202212 16.706 296.797 18.797
202303 16.137 301.836 17.854
202306 17.524 305.109 19.181
202309 19.104 307.789 20.728
202312 20.737 306.746 22.576
202403 21.826 312.332 23.337
202406 23.103 314.175 24.557
202409 24.207 315.301 25.639
202412 24.881 315.605 26.327
202503 23.707 319.799 24.756
202506 23.604 322.561 24.438
202509 25.668 324.800 26.391
202512 27.754 324.054 28.602
202603 29.303 330.213 29.635
202606 30.768 333.952 30.768

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.00 mean?
Neurocrine Biosciences (MIL:1NBIX) has a Cyclically Adjusted Book per Share of €0.00 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' Cyclically Adjusted Book per Share too high?
Neurocrine Biosciences' current Cyclically Adjusted Book per Share is €0.00. Overall, Neurocrine Biosciences has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Cyclically Adjusted Book per Share compare to VTRS and UTHR?
Neurocrine Biosciences' Cyclically Adjusted Book per Share of €0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current Cyclically Adjusted Book per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (MIL:1NBIX) is currently considered Fairly Valued. The stock's GF Value™ is €165.48, compared to a current price of €159.45 — trading 3.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is €0.00. Neurocrine Biosciences' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Neurocrine Biosciences (MIL:1NBIX), the current Cyclically Adjusted Book per Share is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (MIL:1NBIX) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €159.45 is trading 3.6% below its estimated GF Value™ of €165.48. GuruFocus considers Neurocrine Biosciences to be Fairly Valued.

Key valuation signals for MIL:1NBIX:

  • Cyclically Adjusted Book per Share: €0.00
  • GF Value™: €165.48 vs. price of €159.45 (3.6% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the MIL:1NBIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
74GF Score

Get the complete analysis for MIL:1NBIX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€159.45
Price
€165.48
GF Value